In a large cohort comprising 2,818 sporadic pancreatic cancers, our group identified gene mutations in BRCA1, BRCA2, or PALB2 in 1.3%, 3.1%, and 0.6%, respectively. This evidence concerns the gene PALB2 and pancreatic neoplasm.